长沙晚报掌上长沙2月24日讯（全媒体记者 吴鑫矾）项目是发展的载体，今天的项目就是明天的产出。 2月24日，《长沙市2026年推进"五个十大"工作方案》印发，切实发挥示范性重大项目在相关领域的引 领性、支撑性、实效性作用，为加快实现"三高四新"美好蓝图、推动长沙高质量发展贡献力量。 夯实发展根基 锻造核心优势 中车长沙科技创新中心项目是今年的新建项目，将建设人工智能、信息安全等方面研发与应用科技创新 中心，打造中国中车在中南地区的科技创新资源平台、区域研发总部。 提升城市能级 增进民生福祉 让人民群众共享发展成果，是提升幸福指数的关键。在十个重大基础设施项目、十大重点民生实事中， 一系列惠民项目落地见效，诸多民生红利持续释放，将让人民群众满怀期待、倍感振奋。 强化场景开放 打造示范标杆 制造业是长沙的立市之本、强市之基。长沙十个重大产业项目围绕构建"4433"现代化产业体系和17条重 点产业链，以先进制造业为重点，抓好10个技术先进、代表性好、总投资在20亿元以上的产业项目建 设。 比如圣钘科技新一代锂电池研发及综合生产基地项目，预估总投资120亿元，项目达产可满足约100万辆 新能源汽车（含工程机械）或50 ...

Core Insights - Shanghai Yaosu Technology Co., Ltd. is a global leader in "3D-Wet-AI" biotechnology, innovating drug development paradigms through technological advancements [1] - The company was founded in late 2021 in Boston, with a core team from multinational biopharmaceutical companies and top research institutions like Harvard and MIT [1] - Yaosu Technology is the only organ-on-chip company collaborating with the FDA and multinational pharmaceutical alliances to establish next-generation preclinical drug efficacy testing standards [1] Group 1 - The AI image recognition and quantification system for complex 3D organs, developed in collaboration with Pfizer, addresses inefficiencies in traditional pathology assessments in drug development [2] - The system automates, standardizes, and enhances the precision of tissue quantitative analysis, transitioning pathology analysis from subjective human judgment to intelligent quantitative analysis [2] - Key technological advantages include optimized U-Net networks for accurate tissue structure segmentation, a staining standardization module to reduce inter-laboratory staining variability, and a seamless integration into existing pharmaceutical R&D workflows [2] Group 2 - The implementation of this system has improved analysis efficiency by over 50%, with quantitative results closely correlating with traditional pathology scoring in animal model validations [2] - Research findings have been published in the authoritative journal "Toxicologic Pathology" and have been successfully applied in Pfizer's drug development pipeline, with potential for cross-organ and cross-disease applications [2] - This innovative case exemplifies the integration of AI and biomedicine, optimizing R&D cost structures and reducing failure risks, while providing a replicable "AI + Pharmaceutical" integration model for the industry [4] Group 3 - As technology continues to evolve and application scenarios expand, Yaosu Technology aims to leverage its technological advantages to drive the development of digital pathology scanning equipment and cloud service platforms [4] - The company is positioned to inject new momentum into global innovative drug development and facilitate the benefits of precision medicine to a broader population [4]

Core Viewpoint - The collaboration between Guangdong and Macau in the biopharmaceutical and health industry is being promoted through a new model of "Macau R&D + Hengqin Transformation + Guangdong Manufacturing," aiming for high-quality development and internationalization of the industry [1][2][5]. Group 1: Industry Development - The Guangdong-Hong Kong-Macau Greater Bay Area is recognized as a strategic region with significant potential for the biopharmaceutical and health industry [3]. - Guangdong aims to cultivate a biopharmaceutical and health industry cluster with a target scale of 1 trillion yuan by 2027, with the industry cluster generating 663.8 billion yuan in revenue in 2023 [2]. - The Hengqin Guangdong-Macau Deep Cooperation Zone has introduced several supportive measures to promote the high-quality development of the biopharmaceutical and health industry [4]. Group 2: Collaborative Mechanisms - The collaboration focuses on leveraging Macau's international market access and Guangdong's manufacturing capabilities to enhance the biopharmaceutical sector [1][6]. - The "Macau Registration + Hengqin Production" model is encouraged to standardize and internationalize the development of traditional Chinese medicine, innovative drugs, and medical devices [5][6]. - The establishment of the Guangdong-Macau Traditional Chinese Medicine Science and Technology Industrial Park is seen as a key platform for promoting internationalization [5]. Group 3: Economic Impact - The Hengqin Cooperation Zone reported a GDP of 26.313 billion yuan in the first half of the year, with a year-on-year growth of 5%, indicating robust economic activity [4]. - Retail sales in the region reached 2.49 billion yuan, showing a significant year-on-year increase of 42.1%, while total import and export volume surged by 101.5% [4]. Group 4: Market Expansion - The collaboration aims to deepen trade relations with Portuguese-speaking countries and countries involved in the Belt and Road Initiative, enhancing the international market for biopharmaceuticals [6]. - The "Hong Kong-Macau Drug and Medical Device Pass" policy facilitates the free flow of drugs, devices, and patients within the Greater Bay Area, promoting regional medical integration [6][7].

Core Insights - The Zhangjiang Scientific Big Data Innovation Laboratory has officially opened in Shanghai's Pudong New Area, marking a significant step in the market-oriented allocation of data elements in the region [1] - The laboratory focuses on health and medical data, aiming to create a diversified data supply system by integrating municipal, regional, and market data [1] - The laboratory is set to achieve operational effectiveness by 2025, targeting to serve over 100 enterprises, collaborate with more than 10 development entities, and establish over 10 benchmark cases [1] Group 1 - The laboratory employs a strict tiered management system (red, yellow, green zones) to ensure a secure and controllable development environment for biopharmaceutical companies [1] - The initiative aims to enhance the value of data elements and contribute to the high-quality development of leading industries in Pudong New Area [1] - The launch of the laboratory is expected to inject new vitality into the digital economy of Pudong and support the construction of a new ecosystem for the market-oriented allocation of data elements [1] Group 2 - Several biopharmaceutical and data technology companies signed cooperation agreements with the laboratory, covering areas such as data supply, technology development, compliance review, and data pricing [2] - The establishment of the "Pudong Smart Development Expert Database" aims to gather industry experts to provide high-level intellectual support for public data development and utilization [2] - The release of the "Technical Specifications for Trusted Data Space in Health and Medical Fields" provides important technical standards and practical guidelines for data security and compliance in the healthcare sector [2] Group 3 - During a subsequent enterprise forum, companies expressed appreciation for Pudong's innovative mechanisms in promoting the open utilization of public data, particularly in health and medical sectors [3] - Experts from various enterprises provided suggestions for the laboratory's development, emphasizing the need for integration of multi-omics, in vitro experiments, clinical data, medical records, and scientific literature [3] - There is a call for improved supporting services, including comprehensive computational tools, operational environments, and intelligent analysis processes [3]